PetMed Express Inc. filed SEC Form 8-K: Leadership Update
$PETS
Retail-Drug Stores and Proprietary Stores
Consumer Staples
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 8, 2025
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
(561 ) 526-4444
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. o
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 8, 2025, the Board of Directors (the “Board”) of PetMed Express, Inc. (the “Company”) approved an initial annual base salary of $550,000 for Leslie C.G. Campbell, who began serving as the Company’s Interim Chief Executive Officer and President on August 11, 2025. Ms. Campbell’s initial annual base salary will be paid for the period beginning on August 11, 2025, and continuing through such time as the Board and Ms. Campbell enter into a formal employment agreement. The Board also approved that Ms. Campbell would receive the same health and other benefits that the Company provides to its other senior level executives.
Also on September 8, 2025, the Board approved a restricted stock award in the amount of 10,000 restricted shares to Douglas Krulik, the Company’s Chief Accounting Officer and Interim Principal Financial Officer, under the Company’s 2024 Omnibus Incentive Plan (the “Plan”). The award was granted on September 9, 2025. The award will vest in its entirety on the date that is 6 months after the date of grant, subject to Mr. Krulik’s continued employment with the Company through such date, or if earlier, upon the termination of Mr. Krulik’s employment without “cause” within the meaning of the Plan.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 12, 2025
| PETMED EXPRESS, INC. | ||||||||
| By: | /s/ Robert Lawsky | |||||||
| Name: | Robert Lawsky | |||||||
| Title: | General Counsel | |||||||
3